Innovative Therapies for Children with Cancer
Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are recurrent or refractory to standard therapy
T2015-001 A phase I study of Inotuzumab Ozogamycin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy
A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy, and as a single-agent maintenance therapy
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia
A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Single- Agent Ponatinib for the Treatment of advanced Leukemias or Solid Tumors in Pediatric Participants
